Analyzing Peak Bio (PKBO) and The Competition

Earnings & Valuation

This table compares Peak Bio and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Peak Bio	$370,000.00	-$12.83 million	-0.33
Peak Bio Competitors	$575.02 million	-$35.20 million	-23,454.56

Peak Bio’s rivals have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Peak Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-253.92%
Peak Bio Competitors	-4,960.16%	-159.91%	-42.95%

Risk & Volatility

Peak Bio has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Peak Bio’s rivals have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.

Institutional & Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 19.9% of Peak Bio shares are owned by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Peak Bio beats its rivals on 6 of the 9 factors compared.

Peak Bio Company Profile

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.